Literature DB >> 8050813

Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients.

A Mazzocchi1, F Belli, L Mascheroni, C Vegetti, G Parmiani, A Anichini.   

Abstract

The frequencies of cytotoxic T-lymphocyte precursors (CTLp) that lyse autologous tumor by a T-cell receptor (TCR)-dependent mechanism (specific CTLp) were evaluated by limiting dilution analysis (LDA) using lymphocytes from peripheral blood (PBL) and from surgically resected, tumor-invaded lymph nodes (LNL) in 9 melanoma patients. The frequency of specific CTLp was determined in PBLs and/or LNIs of all patients by a modified LDA assay, enabling us to measure lytic activity on the autologous tumor that could be significantly inhibited by an anti-CD3 monoclonal antibody (MAb). This assay allowed us to detect frequencies of specific CTLp ranging from 1/720 to 1/32,037 in peripheral blood and from 1/328 to 1/22,061 in tumor-invaded lymph nodes. These frequencies indicated that lymphoid populations from PBLs or LNLs of melanoma patients may contain as low as 30 to as much as 3,000 specific CTLp/10(6) lymphocytes. In addition, comparison of wells containing specific CTLp with those showing no inhibition by anti-CD3 MAb indicated that specific CTLp represent between 3 and 88% of all precursors with lytic activity on the tumor. In 6 of 9 patients, no marked differences between PBLs and LNIs in specific CTLp frequencies were found. A 10-fold increase of specific CTLp, in comparison to PBL and LNL, was found only in lymphocytes isolated from a subcutaneous metastasis of one patient. Our results indicate that CTLp interacting with autologous tumor by a TCR-dependent mechanism exist in PBL and LNL of most melanoma patients, although a wide variation in their absolute number is evident among different patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050813     DOI: 10.1002/ijc.2910580304

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

Authors:  M Sensi; C Farina; C Maccalli; R Lupetti; G Nicolini; A Anichini; G Parmiani; D Berd
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 2.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

Review 4.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

5.  Frequency determination of breast tumor-reactive CD4 and CD8 T cells in humans: unveiling the antitumor immune response.

Authors:  Mariana Pereira Pinho; Thiago Andrade Patente; Elizabeth Alexandra Flatow; Federica Sallusto; José Alexandre Marzagão Barbuto
Journal:  Oncoimmunology       Date:  2019-05-15       Impact factor: 8.110

Review 6.  Tumor vaccines and beyond.

Authors:  Jan Joseph Melenhorst; Austin John Barrett
Journal:  Cytotherapy       Date:  2010-11-10       Impact factor: 5.414

7.  Estimating point and interval frequency of antigen-specific CD4+ T cells based on short in vitro expansion and improved poisson distribution analysis.

Authors:  Giulia Di Lullo; Francesca Ieva; Renato Longhi; Anna Maria Paganoni; Maria Pia Protti
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

8.  Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.

Authors:  J W Young; K Inaba
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

9.  An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.

Authors:  A Anichini; A Molla; R Mortarini; G Tragni; I Bersani; M Di Nicola; A M Gianni; S Pilotti; R Dunbar; V Cerundolo; G Parmiani
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

10.  High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.

Authors:  Catherine Germeau; Wenbin Ma; Francesca Schiavetti; Christophe Lurquin; Emmanuelle Henry; Nathalie Vigneron; Francis Brasseur; Bernard Lethé; Etienne De Plaen; Thierry Velu; Thierry Boon; Pierre G Coulie
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.